Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer

R. Charles NicholsDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA; Correspondence[email protected]

Christopher G. MorrisDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

Curtis BryantDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

Bradford S. HoppeDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

Randal H. HendersonDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

William M. MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

Zuofeng LiDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

Joseph A. CostaDepartment of Urology, University of Florida College of Medicine, Jacksonville, Florida, USA

Christopher R. WilliamsDepartment of Urology, University of Florida College of Medicine, Jacksonville, Florida, USA

Nancy P. MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA; ;University of Florida Health Proton Therapy Institute, Jacksonville, Florida, USA;

show all

Abstract

Studies demonstrate a decline of ∼10% in serum testosterone (ST) level after X-ray radiotherapy for prostate cancer. We evaluated changes in ST for patients with low- and intermediate-risk prostate cancer receiving 70-82Gy(RBE) using passive-scatter proton therapy (PT). ST was checked at baseline (n = 358) and at 60+ months after PT (n = 166). The median baseline ST was 363.3 ng/dl (range, 82.0–974.0). The median ST 5 years after PT was 391.5 ng/dl (range, 108.0–1061.0). The difference was not statistically significant (p = 0.9341). Passive-scatter PT was not associated with testosterone suppression at 5 years, suggesting that protons may cause less out-of-field scatter radiation than X-rays.

Keywords:

Acknowledgments

The authors would like to thank Jessica Kirwan, MA, and Judy Tran for their editorial assistant and manuscript preparation.

Declaration of interest

The authors have no conflicts of interest to disclose.This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer

Information for

Open access

Opportunities

Help and information

Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer

Abstract

Acknowledgments

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature